ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...

The global cold, cough, and sore throat remedy market is poised for steady growth, with a projected CAGR of 3.40% from 2024 to 2034. The market is estimated to be valued at US$ 42,618.7 million in ...

The global auto-injectors market is set to reach a significant valuation of US$ 30,578.2 million in 2023, marking a strong ...

Diabetes Singapore and GSK aim to enhance awareness and improve lives affected by diabetes through educational talks and activities on World Diabetes Day; 1 in 3 people will get s ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

The Indian pharmaceutical market (IPM) registered a 6.1 per cent value growth in October 2024, with major therapies showing ...

Fitch Solutions has predicted that the naira would slide to as low as N1,993 per dollar in 2028, severely impacting Nigeria’s ...

Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...

BMI has predicted that naira will reach N1,993/$ by 2028, impacting Nigeria’s pharmaceutical industry’s ability to import ...

In an exclusive interview with Nigeria Health Watch, Dr Mukhtar outlined the Executive Order's two-year validity, and its transformative provisions. Central to this includes the removal of tariffs, ...

This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news ...

In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...